Johnson, Douglas B. http://orcid.org/0000-0002-6390-773X
Nebhan, Caroline A.
Moslehi, Javid J.
Balko, Justin M. http://orcid.org/0000-0002-4263-5974
Article History
Accepted: 4 January 2022
First Online: 26 January 2022
Competing interests
: D.B.J. has acted as a consultant and/or advisor for BMS, Catalyst, Iovance, Jansen, Mallinckrodt, Merck, Mosaic ImmunoEngineering, Novartis, Oncosec, Pfizer and Targovax, and receives research funding from BMS and Incyte. D.B.J. and J.J.M. have a patent pending for use of abatacept to reverse ICI toxicities. D.B.J. and J.M.B. have a patent pending for use of MHC II as a biomarker for ICI response. J.M.B. receives research funding from Genentech and Incyte. C.A.N. and J.J.M. declare no competing interests.
Free to read: This content has been made available to all.